Central retinal artery occlusion can result in permanent vision loss. Effective treatment is lacking. We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving ...

Belite Bio completes enrollment in phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt ...

Patients receiving the tafasitamab combination achieved a median PFS of 22.4 months, compared with 13.9 months for patients receiving placebo with lenalidomide and rituximab. This represents a 57% ...

New findings argue against a direct causal role for dopamine during the experience of a treatment effect in the establishment of positive treatment expectations and placebo analgesia in healthy ...

Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...

Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m2 or greater - ...

Andrew Nixon, spokesman for Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., announced on Thursday that moving forward, “all new vaccines will undergo safety testing in ...